Drug Profile
EMD 73495
Latest Information Update: 31 Jan 2001
Price :
$50
*
At a glance
- Originator Merck KGaA
- Class Antihypertensives
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 31 Jan 2001 No-Development-Reported for Hypertension in Germany (Unknown route)
- 12 Nov 1997 Phase-II clinical trials for Hypertension in Germany (Unknown route)
- 26 May 1995 New profile